The clinical trial report, “Alzheimer's Disease - Global Clinical Trials Review, 2026" provides an overview of Alzheimer's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Alzheimer's Disease
- Apr 27, 2026: Voyager IV-Delivered CNS Gene Therapies in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
- Apr 22, 2026: IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
- Apr 20, 2026: Last Patient Has Completed Alzecure’s Phase Ib Clinical Study With Neurorestore ACD856
- Apr 14, 2026: Alzheon to Present Trials with Valiltramiprosate in Alzheimer’s Patients at 2026 American Academy of Neurology Meeting in Chicago, Illinois
- Apr 14, 2026: IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
- Apr 14, 2026: Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
- Apr 09, 2026: NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
- Apr 08, 2026: NeuroTherapia concludes Phase IIa trial of NTRX-07 for Alzheimer's
- Apr 08, 2026: Luye Pharma Announces First Subject Enrolled in the Phase II Clinical Trial in China of the Group’s Innovative Drug LY03020
- Apr 07, 2026: Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors in Phase 1 of ALZ-507
- Apr 07, 2026: IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
- Mar 31, 2026: Annovis Publishes Historical Review of Buntanetap in The Scientist
- Mar 26, 2026: Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 “Lithium in Brain” Study; AL001 Achieves Bioequivalence
- Mar 23, 2026: NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements in Alzheimer’s Disease at AD/PD 2026
- Mar 23, 2026: New Data on Long-Term, Real-World Treatment with Lecanemab Presented at the 2026 AD/PD Congress
- Mar 23, 2026: InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
- Mar 21, 2026: Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD 2026
- Mar 20, 2026: Galimedix Therapeutics Presents Strong Pharmacokinetic Profile of Next-Generation Oral Alzheimer’s Candidate at AD/PD 2026
- Mar 20, 2026: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026
- Mar 19, 2026: AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer's Conference AD/PD
- Mar 19, 2026: ImmunoBrain Presents Clinical Data for First Immune Checkpoint Therapy Approach in Alzheimer's Disease at AD/PD 2026
- Mar 19, 2026: INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early AD
- Mar 19, 2026: CervoMed Announces New Data at AD/PD 2026 Scientific Conference that Reinforce Neflamapimod’s Effects inDLB in Patients without Alzheimer’s Disease
- Mar 19, 2026: AlzeCure presents new preclinical data with NeuroRestore ACD856 at the Alzheimer’s Conference AD/PD
- Mar 18, 2026: Qilu Pharmaceutical’s QLH2405 Received Clinical Approval. Targeting AD via Subcutaneous Injection, Phase I Trial Initiated With 68 Participants
- Mar 17, 2026: Priavoid Presents Initial Phase 2 Data Suggesting Favorable Safety Profile for Alzheimer’s Candidate PRI-002 at AD/PD 2026
- Mar 17, 2026: Acumen Presents Studies on Brain Delivery, Biomarker Research, and Antibodies at Advances in Alzheimer's Treatment at Conference on AD/PD 2026
- Mar 16, 2026: Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in with BD in Collaboration with Massachusetts General Hospital
- Mar 16, 2026: Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease
- Mar 16, 2026: Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD 2026
- Mar 13, 2026: From New Drugs to AI and DTx, Korean Biotechs Take Global Stage at Ad/PD 2026
- Mar 12, 2026: BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
- Mar 12, 2026: Vanqua Bio to Present at the AD/PD 2026 International Conference
- Mar 12, 2026: ImmunoBrain to Present Topline Phase 1b Clinical Data for Immune Checkpoint Treatment in Alzheimer's Disease at AD/PD 2026
- Mar 11, 2026: Latest Data on Long-Term, Real-World Treatment with Lecanemab Will Be Presented at the AD/PD 2026 Congress
- Mar 11, 2026: Arvinas to Present Phase 1 Data for ARV-102, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases
- Mar 10, 2026: NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD 2026
- Mar 10, 2026: Alzheon to Present Clinical, Imaging, and Fluid Biomarker Results from Trials with Oral Valiltramiprosate/ALZ-801 at 2026 AD/PD Conference in Denmark
- Mar 05, 2026: Galimedix Therapeutics to Present Promising Pre-clinical Data with Next Generation Oral Amyloid Beta Aggregation Modulator at AD/PD 2026 Conference
- Mar 05, 2026: Priavoid to Present Initial Phase 2 Safety Data for Alzheimer‘S and Preclinical PoC for Parkinson‘S Programs at AD/PD 2026
- Mar 05, 2026: Alzinova to Participate in Several International Industry and Investor Events During Spring and Summer 2026
- Mar 04, 2026: Transposon Therapeutics’ TPN-101 to Be Studied for Extending Healthy Aging Under ARPA-H Award for up to $22M
- Mar 03, 2026: Annovis Announces Two Presentations at the AD/PD 2026 International Conference
- Mar 03, 2026: Acumen to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
- Feb 25, 2026: Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
- Feb 24, 2026: AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
- Feb 23, 2026: INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
- Feb 23, 2026: IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
- Feb 17, 2026: IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
- Feb 16, 2026: Alzinova Engages Renowned International Alzheimer’s Expert as Global Principal Investigator Ahead of Planned Phase 2 Study
- Feb 12, 2026: Inmune Bio Announces FDA Alignment on Integrated Phase 2B/3 Registration Pathway for XPRO1595 in Early Alzheimer’s Disease
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Source
- Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2026*
- Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2026*
- Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase, 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2026*
- Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2026*
- Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc
- Johnson & Johnson
- Eli Lilly and Co
- Eisai Co Ltd
- Roche Holding AG
- Thermo Fisher Scientific Inc
- ICON Plc
- IQVIA Holdings Inc
- Novartis AG
- AbbVie Inc
